{
  "guideline": {
    "id": "PA166105007",
    "name": "Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6",
    "source": "CPIC",
    "version": 44,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166105007",
    "relatedChemicals": [
      {
        "id": "PA449048",
        "name": "clomipramine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      },
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166297491",
      "name": "Recommendation PA166297491",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060093,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297394",
      "name": "Recommendation PA166297394",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059996,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297531",
      "name": "Recommendation PA166297531",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060133,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297434",
      "name": "Recommendation PA166297434",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060036,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297381",
      "name": "Recommendation PA166297381",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059983,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297544",
      "name": "Recommendation PA166297544",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060146,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297447",
      "name": "Recommendation PA166297447",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060049,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297421",
      "name": "Recommendation PA166297421",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060023,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297553",
      "name": "Recommendation PA166297553",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060155,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297456",
      "name": "Recommendation PA166297456",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060058,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297469",
      "name": "Recommendation PA166297469",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060071,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297398",
      "name": "Recommendation PA166297398",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060000,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297495",
      "name": "Recommendation PA166297495",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060097,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297548",
      "name": "Recommendation PA166297548",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060150,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297416",
      "name": "Recommendation PA166297416",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060018,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297385",
      "name": "Recommendation PA166297385",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059987,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297513",
      "name": "Recommendation PA166297513",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060115,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297482",
      "name": "Recommendation PA166297482",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060084,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301347",
      "name": "Recommendation Annotation PA166301347",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095666,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297500",
      "name": "Recommendation PA166297500",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060102,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297403",
      "name": "Recommendation PA166297403",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060005,
        "html": "<p>Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297372",
      "name": "Recommendation PA166297372",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059974,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297438",
      "name": "Recommendation PA166297438",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060040,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297412",
      "name": "Recommendation PA166297412",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060014,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297535",
      "name": "Recommendation PA166297535",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060137,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297522",
      "name": "Recommendation PA166297522",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060124,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297425",
      "name": "Recommendation PA166297425",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060027,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297487",
      "name": "Recommendation PA166297487",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060089,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297408",
      "name": "Recommendation PA166297408",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060010,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297377",
      "name": "Recommendation PA166297377",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059979,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297474",
      "name": "Recommendation PA166297474",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060076,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297505",
      "name": "Recommendation PA166297505",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060107,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301342",
      "name": "Recommendation Annotation PA166301342",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095661,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297514",
      "name": "Recommendation PA166297514",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060116,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297461",
      "name": "Recommendation PA166297461",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060063,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297364",
      "name": "Recommendation PA166297364",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059966,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297501",
      "name": "Recommendation PA166297501",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060103,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297399",
      "name": "Recommendation PA166297399",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060001,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297496",
      "name": "Recommendation PA166297496",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060098,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297527",
      "name": "Recommendation PA166297527",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060129,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297417",
      "name": "Recommendation PA166297417",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060019,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297443",
      "name": "Recommendation PA166297443",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060045,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297390",
      "name": "Recommendation PA166297390",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059992,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297359",
      "name": "Recommendation PA166297359",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059961,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297478",
      "name": "Recommendation PA166297478",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060080,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297509",
      "name": "Recommendation PA166297509",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060111,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297430",
      "name": "Recommendation PA166297430",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060032,
        "html": "<p>Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297540",
      "name": "Recommendation PA166297540",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060142,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297518",
      "name": "Recommendation PA166297518",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060120,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297465",
      "name": "Recommendation PA166297465",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060067,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297368",
      "name": "Recommendation PA166297368",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059970,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297452",
      "name": "Recommendation PA166297452",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060054,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297355",
      "name": "Recommendation PA166297355",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059957,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297562",
      "name": "Recommendation PA166297562",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060164,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297435",
      "name": "Recommendation PA166297435",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060037,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297382",
      "name": "Recommendation PA166297382",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059984,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297448",
      "name": "Recommendation PA166297448",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060050,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297422",
      "name": "Recommendation PA166297422",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060024,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297532",
      "name": "Recommendation PA166297532",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060134,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297541",
      "name": "Recommendation PA166297541",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060143,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297444",
      "name": "Recommendation PA166297444",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060046,
        "html": "<p>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297554",
      "name": "Recommendation PA166297554",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060156,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297386",
      "name": "Recommendation PA166297386",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059988,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297536",
      "name": "Recommendation PA166297536",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060138,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297483",
      "name": "Recommendation PA166297483",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060085,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297523",
      "name": "Recommendation PA166297523",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060125,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297404",
      "name": "Recommendation PA166297404",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060006,
        "html": "<p>Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297549",
      "name": "Recommendation PA166297549",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060151,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297470",
      "name": "Recommendation PA166297470",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060072,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297373",
      "name": "Recommendation PA166297373",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059975,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297439",
      "name": "Recommendation PA166297439",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060041,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297413",
      "name": "Recommendation PA166297413",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060015,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297263",
      "name": "Recommendation PA166297263",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059865,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301346",
      "name": "Recommendation Annotation PA166301346",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095665,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297545",
      "name": "Recommendation PA166297545",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060147,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297426",
      "name": "Recommendation PA166297426",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060028,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297400",
      "name": "Recommendation PA166297400",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060002,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297395",
      "name": "Recommendation PA166297395",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059997,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297492",
      "name": "Recommendation PA166297492",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060094,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297510",
      "name": "Recommendation PA166297510",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060112,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297528",
      "name": "Recommendation PA166297528",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060130,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297475",
      "name": "Recommendation PA166297475",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060077,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297378",
      "name": "Recommendation PA166297378",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059980,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297462",
      "name": "Recommendation PA166297462",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060064,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297365",
      "name": "Recommendation PA166297365",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059967,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297502",
      "name": "Recommendation PA166297502",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060104,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297497",
      "name": "Recommendation PA166297497",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060099,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297352",
      "name": "Recommendation PA166297352",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059954,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297418",
      "name": "Recommendation PA166297418",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060020,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297387",
      "name": "Recommendation PA166297387",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059989,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297484",
      "name": "Recommendation PA166297484",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060086,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297515",
      "name": "Recommendation PA166297515",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060117,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297405",
      "name": "Recommendation PA166297405",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060007,
        "html": "<p>Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297479",
      "name": "Recommendation PA166297479",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060081,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297431",
      "name": "Recommendation PA166297431",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060033,
        "html": "<p>Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297563",
      "name": "Recommendation PA166297563",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060165,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297466",
      "name": "Recommendation PA166297466",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060068,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301363",
      "name": "Recommendation Annotation PA166301363",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095682,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297369",
      "name": "Recommendation PA166297369",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059971,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297506",
      "name": "Recommendation PA166297506",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060108,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297453",
      "name": "Recommendation PA166297453",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060055,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297356",
      "name": "Recommendation PA166297356",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059958,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297114",
      "name": "Recommendation PA166297114",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059716,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297488",
      "name": "Recommendation PA166297488",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060090,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297519",
      "name": "Recommendation PA166297519",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060121,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297440",
      "name": "Recommendation PA166297440",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060042,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297409",
      "name": "Recommendation PA166297409",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060011,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297550",
      "name": "Recommendation PA166297550",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060152,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297370",
      "name": "Recommendation PA166297370",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059972,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297423",
      "name": "Recommendation PA166297423",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060025,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297555",
      "name": "Recommendation PA166297555",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060157,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297436",
      "name": "Recommendation PA166297436",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060038,
        "html": "<p>Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297410",
      "name": "Recommendation PA166297410",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060012,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297520",
      "name": "Recommendation PA166297520",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060122,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297445",
      "name": "Recommendation PA166297445",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060047,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297392",
      "name": "Recommendation PA166297392",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059994,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297458",
      "name": "Recommendation PA166297458",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060060,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297432",
      "name": "Recommendation PA166297432",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060034,
        "html": "<p>Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297542",
      "name": "Recommendation PA166297542",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060144,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297374",
      "name": "Recommendation PA166297374",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059976,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297524",
      "name": "Recommendation PA166297524",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060126,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297471",
      "name": "Recommendation PA166297471",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060073,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297511",
      "name": "Recommendation PA166297511",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060113,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297361",
      "name": "Recommendation PA166297361",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059963,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297537",
      "name": "Recommendation PA166297537",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060139,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297427",
      "name": "Recommendation PA166297427",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060029,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297396",
      "name": "Recommendation PA166297396",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059998,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297401",
      "name": "Recommendation PA166297401",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060003,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297546",
      "name": "Recommendation PA166297546",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060148,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297493",
      "name": "Recommendation PA166297493",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060095,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297533",
      "name": "Recommendation PA166297533",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060135,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297414",
      "name": "Recommendation PA166297414",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060016,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301345",
      "name": "Recommendation Annotation PA166301345",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095664,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297559",
      "name": "Recommendation PA166297559",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060161,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297480",
      "name": "Recommendation PA166297480",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060082,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297383",
      "name": "Recommendation PA166297383",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059985,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297449",
      "name": "Recommendation PA166297449",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060051,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301344",
      "name": "Recommendation Annotation PA166301344",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095663,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297463",
      "name": "Recommendation PA166297463",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060065,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297516",
      "name": "Recommendation PA166297516",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060118,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297366",
      "name": "Recommendation PA166297366",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059968,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297529",
      "name": "Recommendation PA166297529",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060131,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297498",
      "name": "Recommendation PA166297498",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060100,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297450",
      "name": "Recommendation PA166297450",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060052,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297419",
      "name": "Recommendation PA166297419",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060021,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297560",
      "name": "Recommendation PA166297560",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060162,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297388",
      "name": "Recommendation PA166297388",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059990,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297485",
      "name": "Recommendation PA166297485",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060087,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297538",
      "name": "Recommendation PA166297538",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060140,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297406",
      "name": "Recommendation PA166297406",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060008,
        "html": "<p>Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297375",
      "name": "Recommendation PA166297375",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059977,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297503",
      "name": "Recommendation PA166297503",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060105,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297472",
      "name": "Recommendation PA166297472",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060074,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297467",
      "name": "Recommendation PA166297467",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060069,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297551",
      "name": "Recommendation PA166297551",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060153,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297454",
      "name": "Recommendation PA166297454",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060056,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297357",
      "name": "Recommendation PA166297357",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059959,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297564",
      "name": "Recommendation PA166297564",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060166,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297489",
      "name": "Recommendation PA166297489",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060091,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297441",
      "name": "Recommendation PA166297441",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060043,
        "html": "<p>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301362",
      "name": "Recommendation Annotation PA166301362",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095681,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297476",
      "name": "Recommendation PA166297476",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060078,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297379",
      "name": "Recommendation PA166297379",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059981,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297411",
      "name": "Recommendation PA166297411",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060013,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297543",
      "name": "Recommendation PA166297543",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060145,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297446",
      "name": "Recommendation PA166297446",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060048,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297490",
      "name": "Recommendation PA166297490",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060092,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297393",
      "name": "Recommendation PA166297393",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059995,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297556",
      "name": "Recommendation PA166297556",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060158,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297459",
      "name": "Recommendation PA166297459",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060061,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297433",
      "name": "Recommendation PA166297433",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060035,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297380",
      "name": "Recommendation PA166297380",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059982,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297420",
      "name": "Recommendation PA166297420",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060022,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297530",
      "name": "Recommendation PA166297530",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060132,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297362",
      "name": "Recommendation PA166297362",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059964,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297428",
      "name": "Recommendation PA166297428",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060030,
        "html": "<p>Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297402",
      "name": "Recommendation PA166297402",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060004,
        "html": "<p>Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297397",
      "name": "Recommendation PA166297397",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059999,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297525",
      "name": "Recommendation PA166297525",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060127,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297494",
      "name": "Recommendation PA166297494",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060096,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297512",
      "name": "Recommendation PA166297512",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060114,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297415",
      "name": "Recommendation PA166297415",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060017,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297384",
      "name": "Recommendation PA166297384",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059986,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297481",
      "name": "Recommendation PA166297481",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060083,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297521",
      "name": "Recommendation PA166297521",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060123,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297371",
      "name": "Recommendation PA166297371",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059973,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297424",
      "name": "Recommendation PA166297424",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060026,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297547",
      "name": "Recommendation PA166297547",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060149,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297534",
      "name": "Recommendation PA166297534",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060136,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297437",
      "name": "Recommendation PA166297437",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060039,
        "html": "<p>Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297499",
      "name": "Recommendation PA166297499",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060101,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297504",
      "name": "Recommendation PA166297504",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060106,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297451",
      "name": "Recommendation PA166297451",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060053,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297354",
      "name": "Recommendation PA166297354",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059956,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297517",
      "name": "Recommendation PA166297517",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060119,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301343",
      "name": "Recommendation Annotation PA166301343",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095662,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297486",
      "name": "Recommendation PA166297486",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060088,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297389",
      "name": "Recommendation PA166297389",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059991,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297407",
      "name": "Recommendation PA166297407",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060009,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297376",
      "name": "Recommendation PA166297376",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059978,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297473",
      "name": "Recommendation PA166297473",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060075,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297526",
      "name": "Recommendation PA166297526",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060128,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297539",
      "name": "Recommendation PA166297539",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060141,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297460",
      "name": "Recommendation PA166297460",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060062,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297363",
      "name": "Recommendation PA166297363",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059965,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297429",
      "name": "Recommendation PA166297429",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060031,
        "html": "<p>Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297508",
      "name": "Recommendation PA166297508",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060110,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297455",
      "name": "Recommendation PA166297455",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060057,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297358",
      "name": "Recommendation PA166297358",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059960,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297442",
      "name": "Recommendation PA166297442",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060044,
        "html": "<p>Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297552",
      "name": "Recommendation PA166297552",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060154,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297477",
      "name": "Recommendation PA166297477",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060079,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297561",
      "name": "Recommendation PA166297561",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060163,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297464",
      "name": "Recommendation PA166297464",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060066,
        "html": "<p>Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301361",
      "name": "Recommendation Annotation PA166301361",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449048",
          "name": "clomipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095680,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "27997040",
      "title": "Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.",
      "authors": [
        "Hicks J K",
        "Sangkuhl K",
        "Swen J J",
        "Ellingrod V L",
        "Müller D J",
        "Shimoda K",
        "Bishop J R",
        "Kharasch E D",
        "Skaar T C",
        "Gaedigk A",
        "Dunnenberger H M",
        "Klein T E",
        "Caudle K E",
        "Stingl J C"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2017
    },
    {
      "pmid": "23486447",
      "title": "Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.",
      "authors": [
        "Hicks J K",
        "Swen J J",
        "Thorn C F",
        "Sangkuhl K",
        "Kharasch E D",
        "Ellingrod V L",
        "Skaar T C",
        "Müller D J",
        "Gaedigk A",
        "Stingl J C",
        "Clinical Pharmacogenetics Implementation Consortium"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2013
    }
  ],
  "version": "2023-12-19-10-38"
}